| Description |
Setrusumab (BPS 804) is a fully humanized monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer[1].
|
| Related Catalog |
|
| In Vivo |
Setrusumab (100 mg/kg；每周一次，静脉注射，持续 4 周) 抑制小鼠乳腺癌诱导的骨转移和肌肉无力[1]。 Animal Model: 8-week-old female immune-compromised CB-17/lcr-Prkdcscid/Rj mice with MDA-MB-231 breast cancer cells injection[1] Dosage: 100 mg/kg Administration: Intravenous injection; 100 mg/kg once a week for 4 weeks Result: Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.
|
| References |
[1]. Hesse E, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019 Apr 9;5(9):e125543.
|
